ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
58.64
-0.92 (-1.54%)
Jan 31, 2025, 4:00 PM EST - Market closed
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ANI Pharmaceuticals stock have an average target of 77.33, with a low estimate of 62 and a high estimate of 94. The average target predicts an increase of 31.87% from the current stock price of 58.64.
Analyst Consensus: Buy
* Price targets were last updated on Dec 11, 2024.
Analyst Ratings
The average analyst rating for ANIP stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 2 | 3 | 3 | 4 | 4 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $80 | Buy | Initiates | $80 | +36.43% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $94 | Strong Buy | Reiterates | $94 | +60.30% | Nov 11, 2024 |
| Truist Securities | Truist Securities | Hold Maintains $60 → $62 | Hold | Maintains | $60 → $62 | +5.73% | Oct 22, 2024 |
| Piper Sandler | Piper Sandler | Buy Initiates $68 | Buy | Initiates | $68 | +15.96% | Oct 11, 2024 |
| Raymond James | Raymond James | Buy Maintains $81 → $83 | Buy | Maintains | $81 → $83 | +41.54% | Sep 18, 2024 |
Financial Forecast
Revenue This Year
611.17M
from 486.82M
Increased by 25.54%
Revenue Next Year
739.20M
from 611.17M
Increased by 20.95%
EPS This Year
5.12
from 0.85
Increased by 500.99%
EPS Next Year
5.58
from 5.12
Increased by 8.97%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 631.9M | 784.3M | 843.4M | |||
| Avg | 611.2M | 739.2M | 789.4M | |||
| Low | 585.2M | 685.3M | 714.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 29.8% | 28.3% | 14.1% | |||
| Avg | 25.5% | 20.9% | 6.8% | |||
| Low | 20.2% | 12.1% | -3.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.34 | 6.50 | 7.35 | |||
| Avg | 5.12 | 5.58 | 6.60 | |||
| Low | 4.82 | 4.64 | 6.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 527.7% | 27.0% | 31.8% | |||
| Avg | 501.0% | 9.0% | 18.4% | |||
| Low | 466.3% | -9.4% | 7.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.